Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2019

01-08-2019 | Mastectomy | Brief Report

Radiation oncology crossword: breast cancer

Authors: Shearwood McClelland III, Ryan M. Rhome, Richard C. Zellars

Published in: Breast Cancer Research and Treatment | Issue 1/2019

Login to get access

Excerpt

This is presented as a continuation of our homage to the original Radiation Oncology crossword, updated to reflect the changes in our field in the quarter century since [1]. Following our recent focus on the central nervous system and genitourinary cancer, the focus of this edition is breast cancer [2, 3]. …
Literature
1.
2.
McClelland S 3rd, Jaboin JJ, Thomas CR Jr (2018) Radiation oncology crossword: central nervous system. Int J Radiat Oncol Biol Phys 100:1300–1303CrossRefPubMed
3.
McClelland S 3rd, Mitin T, Thomas CR Jr (2019) Radiation oncology crossword: genitourinary cancer. Rep Pract Oncol Radiother 24:281–283CrossRefPubMed
4.
Bristol IJ, Woodward WA, Strom EA et al (2008) Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncol Biol Phys 72:474–484CrossRefPubMedPubMedCentral
5.
Bartelink H, Horiot JC, Poortmans PM et al (2007) Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 25:3259–3265CrossRefPubMed
6.
Bijker N, Meijnen P, Peterse JL et al (2006) Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24:3381–3387CrossRefPubMed
7.
Poortmans PM, Collette S, Kirkove C et al (2015) Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med 373:317–327CrossRefPubMed
8.
Ratosa I, Jenko A, Oblak I (2018) Breast size impact on adjuvant radiotherapy adverse effects and dose parameters in treatment planning. Radiol Oncol 52:233–244CrossRefPubMedPubMedCentral
9.
Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P (2015) Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol 1:888–896CrossRefPubMed
10.
Correa C, McGale P, Taylor C et al (2010) Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010:162–177CrossRefPubMed
11.
Katz A, Strom EA, Buchholz TA et al (2000) Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol 18:2817–2827CrossRefPubMed
12.
13.
Fouad TM, Barrera AMG, Reuben JM et al (2017) Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system. Lancet Oncol 18:e228–e232CrossRefPubMedPubMedCentral
14.
Morrow M, Van Zee KJ, Solin LJ et al (2016) Society of surgical oncology-American society for radiation oncology-American society of clinical oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. Pract Radiat Oncol 6:287–295CrossRefPubMedPubMedCentral
15.
Shapiro CL, Recht A (2001) Side effects of adjuvant treatment of breast cancer. N Engl J Med 344:1997–2008CrossRefPubMed
16.
Ho AL, Bovill ES, Macadam SA, Tyldesley S, Giang J, Lennox PA (2014) Postmastectomy radiation therapy after immediate two-stage tissue expander/implant breast reconstruction: a University of British Columbia perspective. Plast Reconstr Surg 134:1e–10eCrossRefPubMed
17.
Fisher ER, Land SR, Fisher B, Mamounas E, Gilarski L, Wolmark N (2004) Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ. Cancer 100:238–244CrossRefPubMed
18.
Clarke M, Collins R, Darby S et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366:2087–2106CrossRefPubMed
19.
Darby SC, Ewertz M, McGale P et al (2013) Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368:987–998CrossRefPubMed
20.
Pezner RD, Schultheiss TE, Paz IB (2008) Malignant phyllodes tumor of the breast: local control rates with surgery alone. Int J Radiat Oncol Biol Phys 71:710–713CrossRefPubMed
21.
Jagsi R, Griffith KA, Boike TP et al (2015) Differences in the acute toxic effects of breast radiotherapy by fractionation schedule: comparative analysis of physician-assessed and patient-reported outcomes in a large multicenter cohort. JAMA Oncol 1:918–930CrossRefPubMed
22.
Coles CE, Griffin CL, Kirby AM et al (2017) Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet 390:1048–1060CrossRefPubMedPubMedCentral
Metadata
Title
Radiation oncology crossword: breast cancer
Authors
Shearwood McClelland III
Ryan M. Rhome
Richard C. Zellars
Publication date
01-08-2019
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-019-05304-x

Other articles of this Issue 1/2019

Breast Cancer Research and Treatment 1/2019 Go to the issue

Epidemiology

The use of contralateral prophylactic mastectomy among elderly patients in the United States

Preclinical study

Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome

Epidemiology

Does time to adjuvant chemotherapy (TTC) affect outcomes in patients with triple-negative breast cancer?

Epidemiology

Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database

Epidemiology

Patterns of relapse after neoadjuvant chemotherapy in breast cancer: implications for surveillance in clinical practice

Epidemiology

Is immediate breast reconstruction safe in women over 70? An analysis of the National Surgical Quality Improvement Program (NSQIP) database
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits